Safety first
Guide / Sun & skin safety

Demographic Patterns in U.S. Skin Cancer: Federal Data FAQ

Published October 28, 2026 · MTI Editorial Team · Sources linked on this page

!
Educational information only. Not medical advice and no dosing information. Melanotan I and II sold online are not FDA-approved. Talk to a licensed doctor.
Demographic Patterns in U.S. Skin Cancer: Federal Data FAQ
Photo: "Close-up of a lab technitian adjusting a microscope glass slide" by Shixart1985, CC BY 2.0, via Wikimedia Commons (cropped).

Skin cancer remains the most common form of cancer in the United States. Federal monitoring programs track how diagnoses and risk factors are distributed across different segments of the American public. Understanding these demographic distinctions helps clarify who faces the highest statistical burden and underscores the importance of consulting a qualified physician or dermatologist regarding skin health.

What Types of Skin Cancer Do Federal Registries Monitor?

According to the CDC Skin Cancer Statistics overview, central cancer registries collect data on melanoma of the skin as well as nonepithelial skin cancers, including Merkel cell carcinoma, which is recognized as a rare but often aggressive malignancy. By contrast, registries do not normally collect data on basal cell and squamous cell carcinomas because these conditions occur so frequently.

Even without universal registry recording, specialized surveys measure the extensive health impact of these common keratinocyte carcinomas. An examination of Medical Expenditure Panel Survey data reveals that approximately 6.1 million adults receive treatment for basal cell and squamous cell carcinomas annually, generating an estimated annual cost of $8.9 billion. Further details on these common malignancies are detailed in our guide to types of skin cancer.

How Does Skin Cancer Incidence Differ by Sex?

Federal statistics indicate that skin cancer is not distributed evenly between men and women. Age-adjusted data from SEER registries indicate an overall melanoma incidence rate of 22.3 per 100,000 men and women per year, but sex-stratified breakdowns reveal a higher burden among males:

  • Males across all races: 28.3 new cases per 100,000 persons annually.
  • Females across all races: 17.9 new cases per 100,000 persons annually.

This higher rate among men is also evident in mortality metrics, where the age-adjusted death rate is 2.9 per 100,000 for males across all races compared to the overall population death rate of 2.0 per 100,000 per year.

How Do Diagnosis Rates Vary Across Racial and Ethnic Groups?

Public health records show that melanoma occurs far more frequently in individuals with fair complexion and among non-Hispanic White populations than in any other racial or ethnic group. Long-term exposure to natural or artificial sunlight, including tanning beds, serves as a primary environmental contributor across demographics. A broader look at these variables is explored in our review of who gets melanoma and key demographics.

Age-adjusted incidence rates per 100,000 persons documented by SEER 21 registries illustrate significant variation across racial and ethnic classifications:

  • Non-Hispanic White: 40.7 for males; 27.6 for females.
  • Non-Hispanic American Indian/Alaska Native: 11.3 for males; 7.7 for females.
  • Hispanic: 5.0 for males; 5.0 for females.
  • Non-Hispanic Asian/Pacific Islander: 1.3 for males; 1.2 for females.
  • Non-Hispanic Black: 1.1 for males; 0.9 for females.

At What Ages Are Americans Most Frequently Diagnosed?

Melanoma diagnoses rise markedly with advancing age, showing a median age at diagnosis of 67 years. Although severe outcomes can occur at earlier stages of adulthood, federal surveillance shows that diagnosis before age 20 represents just 0.3% of all cases, and individuals aged 20 to 34 account for 3.8%.

The distribution of new cases increases progressively through midlife and older age:

  • Ages 35 to 44 account for 6.9% of new cases.
  • Ages 45 to 54 represent 11.3%.
  • Ages 55 to 64 represent 21.0%.
  • Ages 65 to 74 represent 27.8%, marking the age band where the disease is most frequently diagnosed.
  • Ages 75 to 84 comprise 20.5%, while individuals older than 84 account for 8.5%.

Mortality rates follow a parallel trajectory, showing higher death rates concentrated among middle-aged and elderly demographics.

How Do Federal Agencies Track Sunburn and Tanning Behaviors?

Because ultraviolet exposure is a controllable hazard, federal programs monitor preventative and risky habits across age groups. The CDC Division of Cancer Prevention and Control statistics page highlights two primary surveillance tools: the Youth Risk Behavior Surveillance System, which surveys high school students regarding indoor tanning and sunburn, and the National Health Interview Survey, which assesses sunburn, indoor tanning, and sun-protective behavior among adults.

Additionally, tools such as the Melanoma Dashboard supply state and local figures to help specific communities address their unique prevention challenges, while the U.S. Cancer Statistics Data Visualizations tool offers accessible government data covering the broader population.

Why Do Demographic Vulnerabilities Make Unregulated Tanning Peptides Dangerous?

Given the established biological risks associated with UV radiation and pigment alterations, individuals seeking a tan often encounter online marketing for melanotan I and melanotan II. These compounds, sold through unregulated internet vendors, are completely unapproved and unregulated by federal health authorities. Bypassing safety regulations with unverified synthetic peptides poses unknown hazards. Anyone concerned about skin changes, sun sensitivity, or family history should avoid unregulated tanning substances and schedule an evaluation with a board-certified dermatologist.

Sources

Centers for Disease Control and Prevention: Skin Cancer Statistics | Skin Cancer | CDC

National Cancer Institute: Melanoma of the Skin — Cancer Stat Facts

Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.